Why this falling FTSE 100 stock could be entering my Buy zone

This writer takes a look at a beaten down FTSE 100 stock that has been sliding lower. Has it reached his Buy zone yet or is it one to watch?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been keeping a close eye on the FTSE 100 in recent months. The large cap index has climbed 7% higher in 2024 but it hasn’t all been plain sailing.

In fact, there are several top stocks under pressure this year. But one pharmaceuticals giant in particular that has caught my eye and could be entering my Buy zone.

Pharma group under pressure

GSK (LSE: GSK) is one of the FTSE 100 stocks that’s on my radar. It’s a famous industry name and one of the largest pharmaceuticals and biotechnology companies in the world.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Despite its status, the GSK share price has been under pressure, falling 26.2% since May 15 to sit at 1,335p per share.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

One of the biggest factors weighing on the group’s valuation has been ongoing lawsuits surrounding its heartburn drug Zantac in the US.

However, GSK has agreed a $2.2bn settlement to end most of these lawsuits with a related £1.8bn charge booked in Q3 this year.

CEO Emma Walmsley said: “[We] resolved the vast majority of Zantac litigation in the quarter, to remove uncertainty and so we can focus forward. All this means we are on track to deliver our 2024 guidance.”

Despite seeing its share price slide in 2024, GSK is still one of the biggest companies in the FTSE 100 with a market cap of £56bn.

Recent performance

GSK reported £8.01bn in Q3 sales back in October which marginally missed analyst estimates of £8.05bn. However, there were some bright spots with core earnings per share (EPS) beating estimates and climbing 5% to 47.9p.

That was driven by 19% growth in Speciality Medicines sales thanks to strong oncology and HIV sales. Another aspect I really like is GSK’s growing pipeline with 11 positive phase-3 trials so far.

However, increasing competition in the respiratory syncytial virus (RSV) market, driven by a US advisory committee’s regulatory guideline revisions, has put a bit of a dampener on the growth outlook.

Valuation

GSK has a price-to-earnings (P/E) ratio of 22 right now. For some context, the Footsie is valued at around 14.5 times earnings.

That premium in itself doesn’t necessarily turn me off. P/E ratios vary by industry, and pharma companies can command a higher premium given the industry’s non-cyclical nature.

I’m more interested in how GSK stacks up against peers. AstraZeneca is a natural comparison as another major global player in the Footsie.

The company is trading at 32.5 times earnings with a £164bn market cap. AstraZeneca has been growing revenue and earnings, driven by organic growth and a number of key acquisitions in recent years.

In fact, management wants to grow total revenue from £45.8bn in 2023 to £80bn by 2030. That’s an ambitious plan, but one that could pay off handsomely for investors.

The verdict

I don’t think GSK is out of the woods yet. Confirmed full-year guidance including sales growth of 7% to 9% and core EPS growth of 10% to 12% certainly helps.

My target multiple for the FTSE 100 stock is 20 times earnings. I think that would compensate me for the risks while being a significant discount to AstraZeneca.

For the moment, I’ll be saving my money so I can buy if GSK falls into my Buy zone.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ken Hall has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »

Investing Articles

Are Trump’s tariffs a once-in-a-lifetime chance for ISA investors to get rich?

The £20,000 Stocks and Shares ISA limit will reset on 6 April. Smart investors could use current market volatility to…

Read more »

Investing Articles

Here are the latest Persimmon share price and dividend forecasts

Our writer looks at the latest forecasts for the Persimmon share price and considers what level of dividend the stock…

Read more »